The STD diagnostics market size has grown strongly in recent years. It will grow from $9.93 billion in 2024 to $10.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to epidemiological trends, healthcare infrastructure development, pharmaceutical developments, sexual education programs, demographic shifts.
The STD diagnostics market size is expected to see rapid growth in the next few years. It will grow to $16.21 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to personalized medicine trends, healthcare access improvements, population health strategies, telemedicine and digital health, rising incidence of STDs. Major trends in the forecast period include point-of-care testing (POCT) advancements, home testing kits, multiplex testing, targeted marketing and outreach, pre-exposure prophylaxis (prep) programs, rising incidence rates.
The escalating prevalence of sexually transmitted diseases (STDs) is a significant driver propelling the STD diagnostics market forward. STDs, infectious diseases transmitted through sexual contact, have become a global health concern. In 2022, the World Health Organization reported that over 1 million sexually transmitted infections are acquired daily worldwide, with approximately 374 million new infections annually, including chlamydia, gonorrhea, syphilis, and trichomoniasis. The rising incidence of STDs underscores the critical role of STD diagnostics in efficient analysis and testing, driving the market's growth.
The increasing healthcare expenditure is anticipated to drive the growth of the STD diagnostics market in the future. Healthcare expenditure refers to the overall amount of money spent on healthcare services, related goods, and activities within a specific healthcare system or economy over a defined period. This expenditure is relevant to STD diagnostics as it signifies a strategic investment in preventive healthcare, addresses public health priorities, and contributes to overall health and well-being at both individual and community levels. For example, in May 2024, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, marking a significant increase compared to the 0.9% growth recorded in 2022. Thus, the rise in healthcare expenditures is fueling the growth of the STD diagnostics market.
The advancement of STD diagnostics is a significant trend within the STD diagnostic market. Major players are enhancing testing facilities and techniques to facilitate quicker and more accurate diagnoses of sexually transmitted diseases. For example, in May 2022, BD (Becton, Dickinson, and Company), a US-based medical technology firm, launched a fully automated, high-throughput molecular diagnostics platform for infectious diseases called the BD CORTM MX/PX System. This platform integrates and automates the molecular laboratory workflow, from sample processing to the delivery of diagnostic test results. The first test available on this new platform is the BD CTGCTV2 molecular assay, which is a single test capable of identifying the three most prevalent non-viral STIs (sexually transmitted infections): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV).
Key companies in the STD diagnostics market are focusing on developing innovative products, such as real-time PCR kits, to meet unmet medical needs and improve diagnostic capabilities. A real-time PCR kit consists of a collection of reagents utilized for conducting real-time polymerase chain reaction (qPCR), a sensitive and commonly employed technique for detecting and quantifying specific nucleic acid sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based research and development company, introduced the Mycoplasma Hominis Real Time PCR Kit and the Treponema Pallidum Real Time PCR Kit, specifically designed for detecting Mycoplasma hominis and Treponema pallidum. These kits offer high sensitivity and specificity, user-friendliness, rapid turnaround times, and the capability to detect multiple pathogens in a single test.
In February 2024, Thyrocare, an India-based healthcare company, acquired Think Health Care for an undisclosed amount. With this acquisition, Thyrocare aims to strategically enhance its service offerings and market reach, especially in the home healthcare segment. Think Health Care is an India-based company specializing in diagnostic and preventive healthcare, known for providing at-home ECG services.
Major companies operating in the STD diagnostics market are Siemens AG, Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech PLC, Binx Health Inc., NOWDiagnostics Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMérieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, InDevR Inc., Karius Inc., Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy.
North America was the largest region in the STD diagnostics market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the std diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the std diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sexually Transmitted Diseases (STDs) diagnostics encompass the examination and identification of infectious conditions transmitted through sexual contact. These diagnostic procedures are essential in determining the presence of STDs within an individual.
The primary categories of STD diagnostics include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, human immunodeficiency virus, chancroid, and other tests performed in laboratory and point-of-care settings. Chlamydia testing involves a urine sample analysis to detect infection. This specific test is employed for identifying chlamydia infections, a common bacterial sexually transmitted infection (STI) transmitted through various forms of sexual contact or genital exposure. These STD diagnostic procedures find application in hospitals, clinics, diagnostic centers, and homecare settings.
The STD diagnostics market research report is one of a series of new reports that provides STD diagnostics market statistics, including STD diagnostics industry global market size, regional shares, competitors with a STD diagnostics market share, detailed STD diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the STD diagnostics industry. This STD diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The STD diagnostics market consists of revenues earned by entities by providing STD diagnostics tests such as cultural/isolated tests of organisms, molecular tests, and immunology assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The STD diagnostics market also includes sales of thermal cyclers, PCR, lateral flow readers - immuno chromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate readers, phone chips, and rapid diagnostic kits which are used in providing STD diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The STD diagnostics market size is expected to see rapid growth in the next few years. It will grow to $16.21 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to personalized medicine trends, healthcare access improvements, population health strategies, telemedicine and digital health, rising incidence of STDs. Major trends in the forecast period include point-of-care testing (POCT) advancements, home testing kits, multiplex testing, targeted marketing and outreach, pre-exposure prophylaxis (prep) programs, rising incidence rates.
The escalating prevalence of sexually transmitted diseases (STDs) is a significant driver propelling the STD diagnostics market forward. STDs, infectious diseases transmitted through sexual contact, have become a global health concern. In 2022, the World Health Organization reported that over 1 million sexually transmitted infections are acquired daily worldwide, with approximately 374 million new infections annually, including chlamydia, gonorrhea, syphilis, and trichomoniasis. The rising incidence of STDs underscores the critical role of STD diagnostics in efficient analysis and testing, driving the market's growth.
The increasing healthcare expenditure is anticipated to drive the growth of the STD diagnostics market in the future. Healthcare expenditure refers to the overall amount of money spent on healthcare services, related goods, and activities within a specific healthcare system or economy over a defined period. This expenditure is relevant to STD diagnostics as it signifies a strategic investment in preventive healthcare, addresses public health priorities, and contributes to overall health and well-being at both individual and community levels. For example, in May 2024, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, marking a significant increase compared to the 0.9% growth recorded in 2022. Thus, the rise in healthcare expenditures is fueling the growth of the STD diagnostics market.
The advancement of STD diagnostics is a significant trend within the STD diagnostic market. Major players are enhancing testing facilities and techniques to facilitate quicker and more accurate diagnoses of sexually transmitted diseases. For example, in May 2022, BD (Becton, Dickinson, and Company), a US-based medical technology firm, launched a fully automated, high-throughput molecular diagnostics platform for infectious diseases called the BD CORTM MX/PX System. This platform integrates and automates the molecular laboratory workflow, from sample processing to the delivery of diagnostic test results. The first test available on this new platform is the BD CTGCTV2 molecular assay, which is a single test capable of identifying the three most prevalent non-viral STIs (sexually transmitted infections): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV).
Key companies in the STD diagnostics market are focusing on developing innovative products, such as real-time PCR kits, to meet unmet medical needs and improve diagnostic capabilities. A real-time PCR kit consists of a collection of reagents utilized for conducting real-time polymerase chain reaction (qPCR), a sensitive and commonly employed technique for detecting and quantifying specific nucleic acid sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based research and development company, introduced the Mycoplasma Hominis Real Time PCR Kit and the Treponema Pallidum Real Time PCR Kit, specifically designed for detecting Mycoplasma hominis and Treponema pallidum. These kits offer high sensitivity and specificity, user-friendliness, rapid turnaround times, and the capability to detect multiple pathogens in a single test.
In February 2024, Thyrocare, an India-based healthcare company, acquired Think Health Care for an undisclosed amount. With this acquisition, Thyrocare aims to strategically enhance its service offerings and market reach, especially in the home healthcare segment. Think Health Care is an India-based company specializing in diagnostic and preventive healthcare, known for providing at-home ECG services.
Major companies operating in the STD diagnostics market are Siemens AG, Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech PLC, Binx Health Inc., NOWDiagnostics Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMérieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, InDevR Inc., Karius Inc., Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy.
North America was the largest region in the STD diagnostics market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the std diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the std diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sexually Transmitted Diseases (STDs) diagnostics encompass the examination and identification of infectious conditions transmitted through sexual contact. These diagnostic procedures are essential in determining the presence of STDs within an individual.
The primary categories of STD diagnostics include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, human immunodeficiency virus, chancroid, and other tests performed in laboratory and point-of-care settings. Chlamydia testing involves a urine sample analysis to detect infection. This specific test is employed for identifying chlamydia infections, a common bacterial sexually transmitted infection (STI) transmitted through various forms of sexual contact or genital exposure. These STD diagnostic procedures find application in hospitals, clinics, diagnostic centers, and homecare settings.
The STD diagnostics market research report is one of a series of new reports that provides STD diagnostics market statistics, including STD diagnostics industry global market size, regional shares, competitors with a STD diagnostics market share, detailed STD diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the STD diagnostics industry. This STD diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The STD diagnostics market consists of revenues earned by entities by providing STD diagnostics tests such as cultural/isolated tests of organisms, molecular tests, and immunology assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The STD diagnostics market also includes sales of thermal cyclers, PCR, lateral flow readers - immuno chromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate readers, phone chips, and rapid diagnostic kits which are used in providing STD diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. STD Diagnostics Market Characteristics3. STD Diagnostics Market Trends and Strategies4. STD Diagnostics Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global STD Diagnostics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the STD Diagnostics Market34. Recent Developments in the STD Diagnostics Market
5. Global STD Diagnostics Growth Analysis and Strategic Analysis Framework
6. STD Diagnostics Market Segmentation
7. STD Diagnostics Market Regional and Country Analysis
8. Asia-Pacific STD Diagnostics Market
9. China STD Diagnostics Market
10. India STD Diagnostics Market
11. Japan STD Diagnostics Market
12. Australia STD Diagnostics Market
13. Indonesia STD Diagnostics Market
14. South Korea STD Diagnostics Market
15. Western Europe STD Diagnostics Market
16. UK STD Diagnostics Market
17. Germany STD Diagnostics Market
18. France STD Diagnostics Market
19. Italy STD Diagnostics Market
20. Spain STD Diagnostics Market
21. Eastern Europe STD Diagnostics Market
22. Russia STD Diagnostics Market
23. North America STD Diagnostics Market
24. USA STD Diagnostics Market
25. Canada STD Diagnostics Market
26. South America STD Diagnostics Market
27. Brazil STD Diagnostics Market
28. Middle East STD Diagnostics Market
29. Africa STD Diagnostics Market
30. STD Diagnostics Market Competitive Landscape and Company Profiles
31. STD Diagnostics Market Other Major and Innovative Companies
35. STD Diagnostics Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
STD Diagnostics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on std diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for std diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The std diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Chlamydia Testing; Syphilis Testing; Gonorrhea Testing; Herpes Simplex Virus Testing; Human Papilloma Virus Testing; Human Immunodeficiency Virus Testing; Chancroid Testing; Other Types2) by Location of Testing: Laboratory Testing; Point of Care (PoC) Testing
3) by End-User: Hospitals and Clinics; Diagnostic Centers; Homecare
Subsegments:
1) by Chlamydia Testing: Nucleic Acid Amplification Tests (NAAT); Antigen Tests2) by Syphilis Testing: Rapid Plasma Reagin (RPR) Tests; Treponemal Tests
3) by Gonorrhea Testing: Nucleic Acid Amplification Tests (NAAT); Culture Tests
4) by Herpes Simplex Virus Testing: PCR Tests; Serological Tests
5) by Human Papilloma Virus Testing: HPV DNA Tests; HPV RNA Tests
6) by Human Immunodeficiency Virus Testing: Antibody Tests; Antigen or Antibody Tests; Nucleic Acid Tests (NAT)
7) by Chancroid Testing: Culture Tests; Nucleic Acid Tests
8) by Other Types: Various Emerging Tests
Key Companies Mentioned: Siemens AG; Abbott Laboratories; Qiagen Inc.; Danaher Corporation; F. Hoffmann-La Roche AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this STD Diagnostics market report include:- Siemens AG
- Abbott Laboratories
- Qiagen Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Bio-Rad Laboratories Inc.
- Becton Dickinson and Company
- Thermo Fisher Scientific Inc.
- Biocartis NV
- Trinity Biotech PLC
- Binx Health Inc.
- NOWDiagnostics Inc.
- Atlas Genetics Ltd.
- BioFire Diagnostics LLC
- BioMérieux SA
- Chembio Diagnostic Systems Inc.
- Corgenix Medical Corporation
- Creative Diagnostics
- Curetis AG
- Daktari Diagnostics
- Enzo Biochem Inc.
- Fujirebio Diagnostics Inc.
- GenePOC Inc.
- GenMark Diagnostics Inc.
- Grifols Diagnostic Solutions Inc.
- Hain Lifescience GmbH
- InDevR Inc.
- Karius Inc.
- Luminex Corporation
- Meridian Bioscience Inc.
- Mesa Biotech Inc.
- Mobidiag Oy
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 10.86 Billion |
| Forecasted Market Value ( USD | $ 16.21 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
